Chongqing Pharmaceutical Research Institute Co., Ltd

Jiangsu Vcare Pharma Tech Co., Ltd.

Institute of Multipurpose Utilization of Mineral Resources

Shanghai Fosun Pharmaceutical Co., Ltd.

Jie Deng

Jie Luo

Wenrun Ye

Yongmei Qin

Bo Lin

Meng Lin

Yong Wu

Yongqiang Liu

Yanchun Gong

Tao Zhang

Wenbin Zhou

Bin Fan

Wenliang Xiong

Zhengyong Zhu

Junlai Luo

Jinmai Xiao

Jinhua Feng

Bo Xiao

Yaoxiang Yue

Chunyan Dan

Huafu Sun

Hao Chen

Jialiang Lin

Shanzhi Deng

Bingyan Chen

Xiangwen Liao

Xiaobo Zeng

Chengqing Ji

Shuping Liu

Yaohui Yang

Disclosed in the present invention are a pyrazolo [1,5-a]pyrimidine derivative having a structure of formula (I), a pharmaceutical composition comprising the compound of formula (I), and use of the compound in the preparation of a medicament for preventing or treating diseases associated with tropomyosin receptor kinases, in particular for preventing or treating cancers associated with tropomyosin receptor kinases. Each substituent in formula (I) has the same definition as that in the description. 

Tropomyosin receptor kinase inhibitor, preparation method therefor and use thereof

The present invention discloses a monazite and apatite paragenetic ore enrichment method. High-grade and high-recovery-rate monazite concentrate can be obtained by adopting the method through steps of ore grinding, floatation, magnetic separation and low-acid advanced leaching treatment and re-floatation. In this process, the applicable range of ore pulp temperature is wide, the process flow is short, the ore dressing conditions are mild, the energy consumption is small, the used diluted acid can be cyclically regenerated and used, the pollution is small, the environmental stress is small and the recovery rate of low-grade monazite and apatite paragenetic ores can be obviously improved.

Monazite and apatite paragenetic ore enrichment method

The present invention provides a stable composition of rasagiline comprising an effective dosage of rasagiline or its pharmaceutically acceptable salts and an antioxidant used as a stabilizer. The dosage forms of the composition are pharmaceutically common transdermal-drug delivery dosage form and mucoadhesive delivery dosage form, such as patch, gel, ointment, cream, cataplasm, film, spray and solution, etc. The composition can be used to prevent or treat mental disorders.

Stable rasagiline composition

A method of purifying a salt of pemetrexed having a structure of formula (III) by salting-out, wherein if Mis H, then each of Mand Mis independently H, Li, Naor K, provided that both of them are not H; if Mis Li, Naor K, then each of Mand Mis independently Li, Naor K. 

Method of purifying a salt, sodium salt and disodium salt of pemetrexed

The present invention relates to morphinan derivatives and preparation methods thereof, especially to ketal hydroxyl protected compounds of morphinan derivatives and preparation method thereof, and to a method for preparing corresponding alkylated morphinan derivatives by using the ketal hydroxyl protected compounds as intermediates, and more especially to a ketal hydroxyl protected compound of methylnaltrexone as intermediate for preparing methylnaltrexone and a method for preparing methylnaltrexone through said intermediate.

Morphinan derivatives and preparation methods thereof

Three new crystalline forms of pemetrexed diacid, preparation methods and uses thereof are disclosed. These preparation processes are simple and have better practicality.

Crystalline forms of Pemetrexed diacid, and preparations thereof

The invention discloses a process for preparing a polynuclear ferric hydroxide-saccharide complex, including: adding an aqueous solution of an alkaline substance drop-wise into an aqueous solution of iron salt at a temperature of 5-20&#xb0; C. until pH 6-8, collecting the polynuclear ferric hydroxide from the reaction mixture by a conventional method; reacting the polynuclear ferric hydroxide with a saccharide in a solution of an alkaline substance for 10-40 hours at 106-125&#xb0; C. under pH 10-12, resulting in a crude product having an isoelectric point of 4.4-5.3 and a weight average molecular weight of 20,000-100,000 Daltons, and then harvesting the polynuclear ferric hydroxide-saccharide complex from the crude product. The process can precisely control the molecular weight of the polynuclear ferric hydroxide-saccharide complex without an effect on the other characteristics of the product, for example its saccharide content or isoelectric point etc. Furthermore, it is very simple and readily applicable in industry.

Process for the preparation of polynuclear ferric hydroxide-saccaride complexes

Growing community of inventors

Chongqing, China

Jie Deng